DelveInsight’s, “Bronchiolitis Obliterans Syndrome (BOS)– Pipeline Insights, 2021,” report provides comprehensive insights about 5+ companies and 10+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Bronchiolitis Obliterans Syndrome: Overview
Bronchiolitis obliterans syndrome is a form of chronic lung allograft dysfunction that affects the majority of lung transplant recipients. It is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous.
Symptoms generally progress slowly over weeks to months. Common symptoms include:
Bronchiolitis obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine; ammonia; oxides of nitrogen or sulfur dioxide; welding fumes; or food flavoring fumes (such as diacetyl). Respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.
A better understanding of BOS pathogenesis is important if rational strategies are to be developed for its management.The histopathological features of BO suggest that injury and inflammation of epithelial cells and subepithelial structures of small airways lead to excessive fibro-proliferation due to ineffective epithelial regeneration and aberrant tissue repair. To support the basis for the pathogenesis of BOS two hypotheses have been proposed by several studies to explain the pathogenesis of chronic rejection which is alloimmune and nonalloimmune mechanisms.
Bronchiolitis Obliterans Syndrome (BOS) remains the major problem which ceases long-term survival after lung transplantation. Treatment and prevention of BOS are quite challenging. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. An important focus of treatment of BOS patients is optimizing immunosuppression to prevent further lung allograft rejection. Current treatment consists primarily of augmenting immunosuppression by changing medications within therapeutic classes, by adding medications, or by applying non-medicinal immuno-modulating therapies. An increasing number of induction and maintenance immunosuppressive agents have become available over time for use in various combinations allowing for more choice and personalization of immunosuppressive therapy.Despite several advancements, there are pros and cons to each immunosuppressive agent and a regimen that leads to prolonged survival yet is void of associated morbidity including infection, malignancy, and drug-related toxicities, etc. are still under regress research and development.
This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Breath Therapeutics a Zambon Group Company (a spin-off of PARI Pharma) is developing Liposomal Cyclosporine A for Inhalation (L-CsA-I; also known as Ciclosporin inhalation and Cyclosporine A Inhalation) as the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS). It is the lead drug candidate and is a proprietary liposomal formulation of cyclosporine A for inhalation administered via a drug-specific investigational PARI Pharma’s eFlow nebulizer, being designed for inhaled delivery to the lungs.
Genentech is developing Pirfenidone, a pyridone small molecule, orally active, an antifibrotic agent that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions, including proliferation and differentiation, and plays a key role in fibrosis. Pirfenidone also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.
Ruxolitinib (also known as INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi and ruxolitinib phosphate) is a small molecule, first-in-class Janus kinase 1 (JAK1)/JAK2 inhibitor. It is developed and marketed by Incyte Corporation, indicated for the treatment of patients with intermediate or high-risk Myelofibrosis and for patients with Polycythemia Vera with inadequate response or intolerance of hydroxyurea.
The drug is approved by the brand name JAKafi in the United States and JAKavi by Novartis outside United States.
Further product details are provided in the report……..
This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. phase III include, Breath Therapeutics and Genentech.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Products have been categorized under various MOA such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Bronchiolitis Obliterans Syndrome: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Bronchiolitis Obliterans Syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Bronchiolitis Obliterans Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bronchiolitis Obliterans Syndrome Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products
• Comparative Analysis
LIPOSOMAL CYCLOSPORINE A: BREATH THERAPEUTICS (A ZAMBON COMPANY)
• Product Description
• Research and Development
• Product Development Activities
PIRFENIDONE: GENENTECH
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products
• Comparative Analysis
RUXOLITINIB: INCYTE CORPORATION
• Product Description
• Research and Development
• Product Development Activities
ALVELESTAT: MEREO BIOPHARMA
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products
• Comparative Analysis
ITACITINIB: INCYTE CORPORATION
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
ALTA-2530: ALTAVANT SCIENCES (A SUBSIDIARY OF SUMITOVANT)
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Bronchiolitis Obliterans Syndrome Key Companies
Bronchiolitis Obliterans Syndrome Key Products
Bronchiolitis Obliterans Syndrome- Unmet Needs
Bronchiolitis Obliterans Syndrome- Market Drivers and Barriers
Bronchiolitis Obliterans Syndrome- Future Perspectives and Conclusion
Bronchiolitis Obliterans Syndrome Analyst Views
Bronchiolitis Obliterans Syndrome Key Companies
Appendix
List of Tables
Table 1 Total Products for Bronchiolitis Obliterans Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Bronchiolitis Obliterans Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• Breath Therapeutics
• Genentech
• Incyte Corporation
• Mereo BioPharma
• Altavant Sciences
• Koutif Therapeutics
